Dabigatran: Uncharted waters and potential harms

Annals of Internal Medicine

Volumn 157, Issue 1, 2012, Pages 66-68

  Radecki, Ryan P ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; APIXABAN; DABIGATRAN; FRESH FROZEN PLASMA; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STROKE; VENOUS THROMBOEMBOLISM;

EID: 84863660210     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-1-201207030-00467     Document Type: Article

References (19)

1. Boehringer bestätigt Todesfälle durch Schlaganfal-Mittel. Der Spiegel; 2011. Accessed at www.spiegel.de/wissenschaft/medizin/gerinnungshemmer-boehringer-bestaeti gt-todesfaelle-durch-schlaganfall-mittel-a-795546.html on 16 May 2012.
2. Moore TJ, Cohen MR, Furberg CD. Signals for Two Newly Approved Drugs and 2010 Annual Summary. QuarterWatch 2010 Quarter 4. Alexandria, VA: Institute for Safe Medication Practices; 2011.
3. U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). Silver Spring, MD: U.S. Food and Drug Administration; 7 December 2011.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. [PMID:21870978]
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. [PMID: 21830957]
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. [PMID:19717844]
7. Moore TJ, Cohen MR, Furberg CD. Signals for Dabigatran and Metoclopramide. QuarterWatch 2011 Quarter 1. Alexandria, VA: Institute for Safe Medication Practices; 2012.
8. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123:2363-72. [PMID: 21576658]
9. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168-75. [PMID: 21972820]
10. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171:1285-6. [PMID: 21788545]
11. Casado Naranjo I, Portilla-Cuenca JC, Jiménez Caballero PE, Calle Escobar ML, Romero Sevilla RM. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis. 2011;32:614-5. [PMID: 22133608]
12. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27. [PMID: 20352166]
13. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran [Letter]. N Engl J Med. 2011;365:2039-40. [PMID: 22111735]
14. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9. [PMID: 21900088]
15. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-9. [PMID: 21998060]
16. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172:397-402. [PMID: 22231617]
17. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11. [PMID: 21041570]
18. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. [PMID: 22077192]
19. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708. [PMID: 21780946]